Inclusion Criteria: - Age: < 18 years - Tumor: Progressive or recurrent low grade glioma, WHO grade 1 or 2 who have failed at least one form of 'conventional' non-surgical therapy - Histologic confirmation is required with the exception of optic pathway and brain stem gliomas. Patients are not required to have a re-operation at time of recurrence. - Patients with disseminated disease are eligible. - Children with neuro-fibromatosis and optic pathway or brainstem tumors are eligible but must have definitive radiologic or clinical evidence of progression - Patients must have evidence of measureable disease - Performance status: Karnofsky or Lansky performance status of >50% - Organ Function: - Adequate bone marrow function (ANC>1000/mm3, platelet count of >75,000/mm3, and hemoglobin > 8gm/dL) prior to starting therapy. Hemoglobin may be supported by transfusion - Adequate liver function (SGPT/ALT<2.5 times ULN and bilirubin < 1.5 times ULN) prior to starting therapy - Prior therapy: - May have had treatment including surgery, chemotherapy, or radiotherapy for any number of relapses prior to enrollment - Patients must have received their last fraction of radiotherapy >12 weeks prior to starting therapy - Previous Vincristine or Vinblastine exposure is allowable. Exclusion Criteria: - No other significant medical illness that in the investigators' opinion cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy - Any other cancer (except non-melanoma skin cancer), unless in complete remission and off of all therapy for that disease for a minimum of 3 years. - Patients of childbearing potential must not be pregnant or breast-feeding (vinorelbine is a pregnancy category D, no data on excretion in breastmilk) - Patients of childbearing or fathering potential must practice adequate contraception